Corcept Therapeutics appoints Renee Gala to board
Ms. Galá is the Senior Vice President and Chief Financial Officer of Theravance Biopharma, a public biopharmaceutical company focused on anti-infectives and diseases of the lung and gastrointestinal tract.
Ms. Galá joined Theravance, Inc. in 2006 and held various roles in the finance organization before leading the separation of the biopharmaceutical business (now Theravance Biopharma) from the royalty company (Innoviva, Inc.) in 2014.
Prior to joining Theravance, Inc., Ms. Galá held positions of increasing responsibility in global treasury, pharmaceutical sales, and corporate strategy/business development at Eli Lilly and Company.
Before that, she worked for seven years in the energy industry, both in the United States and internationally, in positions focused on corporate finance, project finance and mergers and acquisitions.
Ms. Galá holds a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School. ■
LATEST MOVES FROM California
- Peregrine Pharmaceuticals appoints Mark R. Bamforth to boards
- Endologix appoints John Onopchenko as COO
- Depomed appoints Santosh J. Vetticaden as CSO
- Wells Fargo names Michael Roemer as chief compliance officer
- ARMO BioSciences appoints Joseph Leveque as CMO
More inside POST
The art and science of promotional pricing Leadership
What to do with slowly-developing talents Leadership